A look at some of the top headlines trending online today around the world including the latest on another round of winter storms, tensions with Russia, coronavirus developments and much more.
Russia says some troops returning to bases from near Ukraine amid invasion fears (NBC)
Russia-Ukraine standoff: What you need to know now (CBS)
New storm to bring possible severe weather toward South, Midwest (ABC)
Trump Organizations accounting firm says 10 years of financial statements are unreliable (CNN)
Wholesale prices likely surged again in January as inflation accelerates (Fox)
BA.2 Stealth Variant Found in Nearly All U.S. States as Reinfection Capability Unclear (Newsweek)
Vaccine scientists have been chasing variants. Now, theyre seeking a universal coronavirus vaccine (Washington Post)
Amazon and Walmart lift mask rules for vaccinated workers (CBS)
Unvaccinated medical workers turn to religious exemptions (AP)
Canadas Trudeau invokes emergency powers in bid to end protests (Reuters)
Six months of Taliban: Afghans safer, poorer, less hopeful (AP)
Bridgerton Season 2 Trailer Released by Netflix (Hollywood Reporter)
Elon Musk Gave $5.7 Billion of Tesla Shares to Charity Last Year (WSJ)
Actor who faked movie deals sentenced to 20 years in prison for massive Ponzi scheme (LA Times)
Special Report
February 13, 2022 4:45 am
As the omicron variant continues to spread, the national vaccination effort is as urgent as it ever has been. Still, many Americans remain hesitant.
According to a recent survey conducted by the U.S. Census Bureau, 23,830,000 Americans or 9.6% of the 18 and older population say they will either probably or definitely not agree to receive the vaccination.
The share of Americans who will likely refuse vaccination varies considerably nationwide, from as many as 20.5% of the adult population to as little as 3.6%, depending on the state.
Many Americans who have yet to be vaccinated cite one of three reasons: either they are concerned about possible side effects, or they want to wait to see if it is safe, or it is difficult for them to obtain a vaccination. Others cite different reasons.
Nationwide, 14,120,000 people, 5.7% of the adult population, do not trust the COVID-19 vaccines, and another 6,980,000, or 2.8%, do not think COVID-19 is a big threat. Additionally, 12,130,000 American adults, or 4.9% of the 18 and older population, have not been vaccinated because they do not trust the government.
Meanwhile, the virus continues to spread. Since the beginning of the pandemic, there have been 76,448,067 confirmed cases of the virus and a total of 902,189 Americans have died as a result.
So far, 213,430,434 Americans or 65.2% of the total population have received the full course of vaccinations necessary to protect against COVID-19.
All survey data used in this story was published by the Census on Jan. 19, 2022. All data related to COVID-19 infections, fatalities, and vaccinations is current as of Feb. 10, 2022.
ALIEF, Texas - A COVID-19 vaccination drive in Alief is making sure those who want protection against COVID-19 can get a shot.
On Saturday morning, Congressman Al Green, the City of Houston Health Department, Alief ISD, held the drive.
MORE CORONAVIRUS COVERAGE
First doses of the Pfizer, Moderna, and Johnson & Johnson vaccine were made available to the public free of charge.
The drive was held at the Alief Center for Talent and Development Building, located at 14411 Westheimer Road.
SIGN UP FOR FOX 26 HOUSTON EMAIL ALERTS
(Precision Vaccinations)
Texas-basedVaxxinity, Inc. announced results from studies demonstrating the ability of UB-612, its COVID-19 vaccine candidate, to elicit a broad immune response against multiple SARS-CoV-2 virus variants of concern (VoC).
Vaxxinity's press release issued on February 11, 2022, stated UB-612 generated more than three-times higher titers of neutralizing antibodies against the Omicron variantthan an approved mRNA vaccine with boosters.
Sera from 92 participants from UB-612's Phase 2 study, including eight placebos (randomized and tested blinded) and up to 36 participants in the Phase 1 study, half of the latter boosted with a third dose of UB-612, were used in these studies to analyze binding of IgG and neutralization against multiple VoCsand Variantsincluding Omicron.
UB-612 is the first multitope protein/peptide-based vaccine candidate for SARS-CoV-2.
The vaccine candidate is designed to activate both B and T-cell arms of the immune system.
"The ability of these sera to neutralize Omicron at these high levels is extraordinary and unprecedented considering that Omicron has more than 30 potential immune evading mutations and deletions across its spike protein, 15 of which are in the RBD region where our UB-612 vaccine is directed."
"Such data show that UB-612 could potentially be a unique vaccine candidate that is highly effective at mobilizing the immune system against a broad range of both current and future SARS-CoV-2 variants," said Farshad Guirakhoo, Ph.D., Chief Scientific Officer at Vaxxinity.
The studies were conducted by David Goldblatt, M.B. Ch.B., Ph.D., at University College Londonand VisMederi, a Coalition for Epidemic Preparedness Innovations-centralized laboratory.
Vaxxinity confirmed plans to publish these UB-612 data and present the findings at World Vaccine Congress in April 2022.
Vaxxinity, Inc. is a purpose-driven biotechnology company located in Dallas, TX, committed to democratizing healthcare globally.
A COVID-19 vaccine sprayed in the nostrils might supplant shots in the arm.
Intranasal vaccines against COVID-19 are already in development worldwide and could provide more long-lasting protection, as it starts in the place where the pathogen lands: the mucous membranes in the airways.
The vaccines work by triggering the production of an antibody known as immunoglobulin A, which can block infection and reduce the risk of spreading the virus to others. Unlike the mRNA vaccines given as intramuscular injections in the upper arm that the United States has embraced, the spray would be painless an attractive feature for children and the needle-phobic.
Intranasal vaccines have not gotten the government support needed to develop the COVID-19 vaccines currently on the U.S. market. But researchers worldwide are in varied phases of studies. For instance, India-based Bharat Biotech, maker of the Covaxin COVID-19 vaccine, recently won approval from the countrys health regulators to enroll human subjects in clinical trials of an intranasal booster dose of immunity. The company plans to enroll nearly 5,000 people who received Covaxin in the trials.
CALIFORNIA INITIATIVE WOULD MANDATE COVID-19 VACCINES FOR ALL WORKERS
In Australia, respiratory scientist Daniela Traini at Sydneys Macquarie University received a $100,000 grant (around $72,000 U.S. dollars) from the Government of New South Wales to work with Sydney-based biotech company Medlab on an mRNA vaccine for COVID-19 to be delivered nasally.
If this study is successful, it would possibly allow other mRNA vaccines to be delivered by nasal spray, and it would bring a number of benefits, Traini said.
Researchers also believe the nasal spray vaccines could be transported more easily than the traditional mRNA vaccines, which require refrigeration at extremely low temperatures to stay viable around minus 94 degrees Fahrenheit. The relative ease the intranasal vaccines could be stored with would be a game-changer for vaccinating people in developing countries, according to Traini.
Another recent study of an intranasal vaccine using an engineered version of the coronavirus given to chimpanzees found it induced all-around immunity against the original strain of the coronavirus, as well as the alpha and beta strains. The group of Canadian immunologists behind the study concluded the intranasal vaccine represents an effective next-generation COVID-19 vaccine strategy to induce all-around mucosal immunity against current and future [variants of concern].
CLICK HERE TO READ MORE FROM THE WASHINGTON EXAMINER
Despite a general lack of funding for the development of intranasal COVID-19 vaccines in the U.S., they have received strong support from big names in the science field. Eric Topol, director of the Scripps Research Translational Institute and data scientist, said it is imperative that new investments in vaccine research and development include substantial funding for intranasal vaccines.
He and co-writer Daniel Oran, also a member of the Scripps Research Translational Institute, further called intranasal vaccines a smart bet.
COVID-19 is showing signs of transitioning from a pandemic to a phase in which the virus becomes a regular facet of normal life. But new variants are expected to arise and pose the risk of evading vaccine-conferred protection. A vaccine that coats the entire mucous membrane could help keep the coronavirus from taking up residence in the airways.
This is an excerpt from Second Opinion, a weekly health and medical science newsletter.If you haven't subscribed yet, you can do that by clickinghere.
COVID-19 vaccine mandates have worked extraordinarily well at getting more Canadians vaccinated, but they are increasingly hard to justify not because of protests or political pressure but because they're a victim of their own success.
Vaccinations have been mandated for certain jobs, such ashealth-care workers and federal public servants, while vaccine passports have been put in place for non-essential services such as gyms, bars and restaurants for the general population.
And they've been an undeniable success: lifting Canada's vaccination rate to one of the highest in the world, protecting vulnerable sectors of society such as hospitals and long-term care and helping us achieve one of the lowest rates of death in the developed world.
"There's now obvious evidence that they work," Canada's Chief Public Health Officer, Dr. Theresa Tam, said during a press conference Friday.
"We saw a plateau in the uptake of vaccines after a really tremendous effort by Canadians, and then after the introduction of vaccine mandates by the various provinces and territories and jurisdictions, we did see an uptick."
Health Minister Jean-Yves Duclos added that mandates worked to get 99 per cent of federal public servants vaccinated, and that over the last six months as many as three million Canadians chose to get vaccinated sooner because of them.
"Vaccination is not punishment.Vaccination is protection," he said. "Let's imagine what the situation with Omicron would now be if we had up to three million Canadians not vaccinated."
WATCH |Experts say ending vaccine mandates too soon could undo what's been accomplished:
But as the massive Omicron-driven fifth wave subsides across Canada and public health restrictions are set to lift, infectious disease experts and epidemiologists say two-dose mandates are no longer sufficient and mandating boosters is not a realistic approach.
That's because while two doses are still effective at preventing severe illness, the highly transmissible Omicron variant has rendered them less protective against infection and transmission to others than with previous coronavirus strains.
But recent research from Canada and around the world has shown there is substantially more protection against Omicron infection with a third dose and that boosters are significantly more effective against severe illness than with two doses alone.
A new analysis of vaccine effectiveness in both British Columbia and Quebec, which is set to be released in the coming days as a preprint study, found third doses were about 60 per cent effective against Omicron infection and more than 90 per cent against severe disease.
"For three doses, we see that the vaccine effectiveness against all outcomes is jacked up," said Dr. Danuta Skowronski, a vaccine effectiveness expert and epidemiology lead at the British Columbia Centre for Disease Control, who co-authored the study.
"The vaccine is more effective in preventing severe outcomes."
Skowronski's findings are similar to those in a recent U.K. analysis that found the level of protection against symptomatic infection from three doses jumped to 63 per cent against Omicron and 70 per cent against the BA.2 subvariant two weeks following a booster shot.
A recently updated Ontario study also found that while vaccines were just 36 per cent effective against symptomatic Omicron infection seven to 59 days after two doses, with no protection after six months, that increased to 61 per cent a week after a booster.
"Boosters work, they're worthwhile and they're needed to prevent Omicron transmission," said Maria Sundaram, an infectious diseases epidemiologist and post-doctoral fellow at the University of Toronto's Centre for Vaccine Preventable Diseases, and co-author of the study.
"Vaccine mandates are a way to try to strengthen that tool, but vaccines have never been the only thing that will help us end this pandemic."
Dr. Allison McGeer, a medical microbiologist and infectious diseases specialist at Toronto's Mount Sinai Hospital, said Canada now needs to make an "extraordinarily difficult" call on whether to expand vaccine mandates and passports or abolish them altogether.
"We've got to make a decision about whether we're not having them or whether we're going to three doses," she said. "Because two doses is no longer very functional and the situation has changed completely because of Omicron."
If we were to keep the definition of "fully vaccinated" as having had two doses, vaccine mandates will accomplish "very little," Dr. Isaac Bogoch, an infectious diseases physician and member of Ontario's COVID-19 vaccine task force, said on The Current Wednesday.
"There's no point in keeping it around other than that it's a tool to maybe encourage people to get vaccinated, which if we are using it for that tool it's already run its course," he said.
"So you either say we're doing this as a three-dose vaccine series to be considered fully vaccinated or you scrap it."
One key unanswered question with regard to whether we should expand or abolish vaccine mandates in Canada is how long the protection from a third dose lasts and we're getting some early hints that booster protection may not be as long-lasting as we'd hoped.
New data from the U.S. Centers for Disease Control and Prevention released Friday found booster protection waned after about four months, highlighting the potential need for fourth doses in the high risk, and dealing a major blow to the case for expanding mandates.
The analysis of 241,204 emergency department and urgent care centre visits in 10 states found vaccine effectiveness dropped from 69 per cent within two months of a second dose to just 37 per cent after five months.
That protection increased to 87 per cent with a booster, but dropped down to 66 per cent between four and five months and fell to just 31 per cent after five or more months.
The researchers stressed that the data is limited given the small number of Americans who are more than five months out from a booster, and the analysis also did not include a breakdown of the data by age or whether the booster recipient was immunocompromised.
Still, the data shows booster effectiveness can drop in the mere months after a third dose. Thiscallsinto question the role that vaccine mandates and passports will play in the future, and highlightsthe growing need to update our vaccines.
The vaccines currently used were made to target the original strain of the virus that is dramatically different from Omicron, which has quickly become dominant globally in the months since it was identified.
"We are using vaccine right now that is based on the original Wuhan-like strain though the circulating virus has continued to evolve," Skowronski said.
"So the question is, how much added gain are we getting by giving additional doses of that Wuhan-like antigen as the Omicron surge subsides? And that remains, I think, an open question."
WATCH | Experts warn a rushed return to normal could backfire:
Maria Van Kerkhove, an infectious diseases epidemiologist and the WHO's technical lead on COVID-19, said Omicron won't be the final variant of concern the world sees and that the next one will likely be more transmissible in order to overtake current circulating strains.
"The big question is whether or not future variants will be more or less severe,"she said during a press conference Tuesday.
"We know a lot about this virus, but we don't know everything. And quite frankly, the variants are the wild card. So we are tracking this virus in real time as it mutates, as it changes, but this virus has a lot of room to move."
Whether or not a future variant-driven surge of COVID-19 levels in Canada could change the need for vaccine mandates in the future remains an open question, but for now the pressure to lift mandates and other restrictions continues to mount.
"It's very tough, because I'm watching different communities go through this and say, 'Well, obviously we're really done with COVID-19. We're really done with it.' And I totally understand, because I'm also really done with it," said Sundaram.
"The thing is, it's not done with us."
The Centers for Disease Control and Prevention (CDC)s National Center for Immunization and Respiratory Diseases, and the Centers Deputy Director for Science have expressed gratitude to the nations Cooperative Extension System, including University of Tennessee Extension, for addressing vaccine hesitancy by educating and raising awareness about the importance of getting vaccinated for COVID-19 in rural America.
Rural America continues to be especially hard hit by the pandemic, and the lives of families and communities continue to feel the impacts, said Director of the USDAs National Institute of Food and Agriculture (NIFA) Dr. Carrie Castille. Because our communities are faced with making important decisions about vaccinations, having a trusted, independent community agent to aid in decision making is essential. Cooperative Extension agents and educators are well placed to have that discussion and provide objective educational information. Talk with your Extension agent, and then decide.
Through an interagency agreement with the CDC and NIFA, Cooperative Extension units at land-grant universities across the nation received funding and launched the Cooperative Extension Immunization Teaching and Engagement (EXCITE) in June 2021 to address health disparities among rural and other underserved communities.
Acting director of the CDC National Center for Immunization and Respiratory Diseases Samuel F. Posner said in a letter to the U.S. Cooperative Extension System, Agents and educators are trusted messengers working in every county across the nation and are uniquely situated at local levels to engage with their communities and build partnerships to improve community health.
As my team listens to our partners in the field, we hear story upon story of the need for one-on-one, honest discussions with trusted messengers to address concerns about COVID-19 vaccines, said Posner.
UT Extension is proud to be one of the 24 Extension agencies across the nation addressing vaccine hesitancy issues. UT Extensions EXCITE project team includes state and county-based Family and Consumer Sciences personnel, as well as nursing faculty from the UT Health Science Center. To ensure maximal local involvement, participating counties have recruited Community Advisory Boards and held community conversations to uncover the attitudes and concerns that underlie vaccine hesitancy in their locations. Girded with this knowledge and support, the team is developing tailored educational campaigns to encourage COVID-19 and other adult vaccine uptake that are community-inspired and motivational, fully informed by county-based advisory boards and focus groups.
Tailored messaging in rural areas works, said Posner. As of today, over 76% of people in the United States have received their first COVID-19 vaccine dose. In rural areas, 71.4% of people ages 18 and older have received at least one dose of a COVID-19 vaccine with the percentage of those reporting that they definitely will get vaccinated on the incline. Thank you to those who helped realize these achievements by getting vaccinated and helping others do the same.
To reach the remaining individuals who are hesitant about receiving a COVID-19 vaccine, we are relying on trusted messengers to provide education about the vaccines, share information on how they were developed, and address myths about whats in the vaccines, he said. Theres an enormous need to cut through the confusion that exists about why everyone should receive a vaccination, how to get a vaccine, where to get vaccinated, and what services are available to get them to the point of vaccination (if needed).
The CDC recently published a COVID-19 Vaccination Field Guide Addendum: Rural Considerations for Vaccine Confidence and Uptake Strategies. This resource complements CDCs 12 COVID-19 Vaccination Strategies for Your Community and content on How to Conduct a Rapid Community Assessment, both designed to support the work of communities across the U.S. to increase vaccine confidence and vaccine uptake.
I know how hard field agents work, the long hours and distances traveled especially in rural and frontier areas, and how much you all care about the community members you serve. Thank you for all that you do! Posner said.
The Cooperative Extension System is operated through the nations land-grant university system in partnership with the federal and state and local governments. As the federal partner, NIFA develops methods to address national priorities, funds and awards grants, and provides program leadership. The agency supports both the universities and local Extension offices to bring science directly to the regional and county level.
NIFA invests in and advances agricultural research, education, and Extension across the nation to make transformative discoveries that solve societal challenges. NIFA supports initiatives that ensure the long-term viability of agriculture and applies an integrated approach to ensure that groundbreaking discoveries in agriculture-related sciences and technologies reach the people who can put them into practice. In FY2020, NIFAs total investment was $1.95 billion.
Through its land-grant mission of research, teaching and extension, the University of Tennessee Institute of Agriculture touches lives and provides Real. Life. Solutions. utia.tennessee.edu.
What you need to know
COVID-19 vaccines are safe for children and adults
While COVID-19 vaccines were developed quickly, all steps have been taken to ensure their safety and effectiveness.
A growing body of evidence shows that the benefits of COVID-19 vaccination outweigh the known and potential risks. CDC recommends an mRNA COVID-19 vaccine (Pfizer-BioNTech or Moderna) in most circumstances based on an updated risk-benefit analysis.
Before recommending COVID-19 vaccines, including for children ages 5 years and older, scientists conducted clinical trials with thousands of adults and children and found no serious safety concerns. Learn more about the benefits of COVID-19 vaccination for children and teens.
COVID-19 vaccination is a safer way to build protection
Getting a COVID-19 vaccination is a safer way to build protection than getting sick with COVID-19. COVID-19 vaccination helps protect you by creating an antibody response without you having to experience sickness.
Getting sick with COVID-19 can have serious consequences.
COVID-19 vaccines are effective
COVID 19-vaccines are effective and can lower your risk of getting and spreading the virus that causes COVID-19. COVID-19 vaccines also help prevent serious illness and death in children and adults, even if they do get COVID-19.
Viruses are constantly changing, including the virus that causes COVID-19. These changes occur over time and can lead to the emergence of variants that may have new characteristics. Vaccines continue to reduce a person's risk of contracting the virus that cause COVID-19. Vaccines are highly effective against severe illness.
COVID-19 vaccination is a more reliable way to build protection
The level of protection people get from having COVID-19 (sometimes called natural immunity) may vary depending on how mild or severe their illness was, the time since their infection, and their age; and there is still not an antibody test available that can reliably determine if a person is protected from further infection.
All COVID-19 vaccines currently available in the United States are effective at preventing COVID-19. Staying up to date with COVID-19 vaccination gives most people a high level of protection against COVID-19.
You should get a COVID-19 vaccine, even if you already had COVID-19. Emerging evidence shows that getting a COVID-19 vaccine after you recover from COVID-19 illness provides added protection to your immune system.
Once Up to Date on COVID-19 Vaccination, You Can Start Doing More
When you are up to date on COVID-19 vaccination, you can resume many activities with proper precautions (e.g., wearing a mask while indoors in public spaces).
Additional Resources
A girl making her way to school in Abuja, Nigeria, last year.Credit...Afolabi Sotunde/Reuters
A new study of underreported coronavirus variants is serving as a reminder that early detection and frequent genomic sequencing are among the most effective arrows in the quiver of public health officials.
But that is precisely what is not happening in many countries, putting their own populations as well as the rest of the world at greater risk.
Researchers in the United States and Nigeria examined a variant of interest, Eta, that circulated in Nigeria in early 2021, as well as a rare Delta sublineage in the region that was different from the Delta variant that circulated in the rest of the world.
Eta may have warranted designation as a variant of concern had its growth potential been recognized earlier, wrote the researchers from Northwestern Universitys Feinberg School of Medicine and the University of Ibadan in Nigeria. Their research was published this month in Nature Communications.
We were just lucky that this variant did not spread globally, said Dr. Oyewale Tomori, a virologist who leads a Nigerian government committee on Covid-19.
Judd Hultquist, a co-author of the report and the associate director of the Center for Pathogen Genomics and Microbial Evolution at Northwestern, said tracking of variants was incredibly uneven across the world.
Less than 1 percent of sequences are from the continent of Africa, and less than 3 percent are coming from South America, he said in an interview.
On Thursday, the World Health Organizations Africa director, Dr. Matshidiso Moeti, encouraged wider use of genomic-sequencing technology in Africa to help speed up the detection of new variants. The technology is available only in a few of the regions middle-income countries, like South Africa and Botswana.
Researchers from around the world use GISAID, the online global repository of coronavirus sequences, to share new genomes and scan for mutations in its hundreds of thousands of viral genetic sequences.
Nigeria, with a population of 220 million people, is the worlds seventh most populous country and the largest Black-majority nation. It is also one of the least vaccinated: Less than 3 percent of its population is fully inoculated, according to the Our World in Data project at the University of Oxford.
The World Health Organization labeled Eta a variant of interest, meaning it was worth studying but not as dangerous as a variant of concern. But after Eta displaced the Alpha variant in Nigeria and the surrounding region early last year, the researchers found that it went largely unnoticed while Alpha remained the focus of much of the world.
Eta had all the characteristics of a variant of concern, and it was able to outcompete the Alpha variant in the region before the arrival of Delta, Dr. Hultquist said.
And after Etas rise and fall, a rare Delta sublineage (AY.36) appeared in the region that was different from the Delta variant that circulated in most of the world.
The study emphasizes the critical need to improve surveillance and monitoring coronavirus infections to ensure early detection of new variants in Nigeria and the West Africa region, said Dr. Moses Adewumi of the University of Ibadan, one of the collaborators.
Even now, the researchers said, there are only just over 1,400 coronavirus sequences from Nigeria available in public repositories. The United States, by comparison, is sequencing tens of thousands of specimens each week.
The variants that were scrutinized by researchers are no longer a threat. But at the time variants of Alpha and Eta produced the highest peak of new infections; and the rare Delta lineage caused the second peak, according to Dr. Ramon Lorenzo-Redondo of Northwestern, one of the studys authors. The peaks brought the highest death rates of the pandemic, he said.
Africa is not fully utilizing available lab resources, Dr. Tomori said. He said the continents labs had sequenced 70,000 viral genomes by the end of 2021.
There is inadequate sequencing going on in Africa, because many African governments have not appreciated the usefulness of such facilities in providing data for better control of epidemics, he said. Also, there is a lack of collaboration among African researchers, some of whom prefer to work with their past colonial colleagues.
One lesson is clear: Its never too early to try to tell what the impact of a variant might be. Researchers are already keeping a close eye on a new Omicron sub-variant, BA.2.
Alex Sigal, a virologist at the Africa Health Research Institute in Durban, South Africa, who helped identify the Beta and Omicron variants, said: The bigger message here is that were not seeing everything, and that some of these places may not have control of Covid-19.
The vaccine deployment in December 2020 signaled a turning point in the COVID-19 pandemic. By the end of May 2021, 40% of the U.S. population was fully vaccinated. But as vaccination rates lagged over the summer, new surges of COVID-19 came, including Delta in the summer of 2021, and now the Omicron variant, which comprises the majority of cases in the U.S.
Researchers around the world have reported that Omicron is more transmissible than Delta, making breakthrough and repeat infections more likely. Early research suggests this strain may cause less severe illness than Delta and the original virus, however, health officials have warned an Omicron-driven surge could still increase hospitalization and death rates especially in areas with less vaccinated populations.
The United States as of Feb. 11 reached 917,622 COVID-19-related deaths and 77.5 million COVID-19 cases, according to Johns Hopkins University. Currently, 64.3% of the population is fully vaccinated, and 42.6% have received booster doses.
Stacker compiled a list of the counties with highest COVID-19 vaccination rates in Nevada using data from the U.S. Department of Health & Human Services and Covid Act Now. Counties are ranked by the highest vaccination rate as of Feb. 10, 2022. Due to inconsistencies in reporting, some counties do not have vaccination data available. Keep reading to see whether your county ranks among the highest COVID-19 vaccination rates in your state.
Population that is fully vaccinated: 21.5% (887 fully vaccinated) 63.6% lower vaccination rate than Nevada Cumulative deaths per 100k: 218 (9 total deaths) 27.6% less deaths per 100k residents than Nevada Cumulative cases per 100k: 7,810 (322 total cases) 64.2% less cases per 100k residents than Nevada
Population that is fully vaccinated: 26.6% (539 fully vaccinated) 54.9% lower vaccination rate than Nevada Cumulative deaths per 100k: 0 (0 total deaths) 100.0% less deaths per 100k residents than Nevada Cumulative cases per 100k: 14,638 (297 total cases) 32.8% less cases per 100k residents than Nevada
Population that is fully vaccinated: 35.5% (2,389 fully vaccinated) 39.8% lower vaccination rate than Nevada Cumulative deaths per 100k: 431 (29 total deaths) 43.2% more deaths per 100k residents than Nevada Cumulative cases per 100k: 20,595 (1,385 total cases) 5.5% less cases per 100k residents than Nevada
Population that is fully vaccinated: 37.9% (1,963 fully vaccinated) 35.8% lower vaccination rate than Nevada Cumulative deaths per 100k: 96 (5 total deaths) 68.1% less deaths per 100k residents than Nevada Cumulative cases per 100k: 19,197 (995 total cases) 11.9% less cases per 100k residents than Nevada
Population that is fully vaccinated: 39.1% (2,164 fully vaccinated) 33.7% lower vaccination rate than Nevada Cumulative deaths per 100k: 289 (16 total deaths) 4.0% less deaths per 100k residents than Nevada Cumulative cases per 100k: 20,119 (1,113 total cases) 7.7% less cases per 100k residents than Nevada
Population that is fully vaccinated: 40.5% (354 fully vaccinated) 31.4% lower vaccination rate than Nevada Cumulative deaths per 100k: 344 (3 total deaths) 14.3% more deaths per 100k residents than Nevada Cumulative cases per 100k: 9,966 (87 total cases) 54.3% less cases per 100k residents than Nevada
Population that is fully vaccinated: 40.5% (6,816 fully vaccinated) 31.4% lower vaccination rate than Nevada Cumulative deaths per 100k: 285 (48 total deaths) 5.3% less deaths per 100k residents than Nevada Cumulative cases per 100k: 26,012 (4,378 total cases) 19.3% more cases per 100k residents than Nevada
Population that is fully vaccinated: 40.9% (23,497 fully vaccinated) 30.7% lower vaccination rate than Nevada Cumulative deaths per 100k: 273 (157 total deaths) 9.3% less deaths per 100k residents than Nevada Cumulative cases per 100k: 18,030 (10,369 total cases) 17.3% less cases per 100k residents than Nevada
Population that is fully vaccinated: 41.0% (21,654 fully vaccinated) 30.5% lower vaccination rate than Nevada Cumulative deaths per 100k: 243 (128 total deaths) 19.3% less deaths per 100k residents than Nevada Cumulative cases per 100k: 22,862 (12,066 total cases) 4.9% more cases per 100k residents than Nevada
Population that is fully vaccinated: 45.5% (21,191 fully vaccinated) 22.9% lower vaccination rate than Nevada Cumulative deaths per 100k: 466 (217 total deaths) 54.8% more deaths per 100k residents than Nevada Cumulative cases per 100k: 14,285 (6,646 total cases) 34.5% less cases per 100k residents than Nevada
Population that is fully vaccinated: 50.4% (24,639 fully vaccinated) 14.6% lower vaccination rate than Nevada Cumulative deaths per 100k: 168 (82 total deaths) 44.2% less deaths per 100k residents than Nevada Cumulative cases per 100k: 15,863 (7,758 total cases) 27.2% less cases per 100k residents than Nevada
Population that is fully vaccinated: 51.8% (4,959 fully vaccinated) 12.2% lower vaccination rate than Nevada Cumulative deaths per 100k: 188 (18 total deaths) 37.5% less deaths per 100k residents than Nevada Cumulative cases per 100k: 19,864 (1,903 total cases) 8.9% less cases per 100k residents than Nevada
Population that is fully vaccinated: 52.0% (12,951 fully vaccinated) 11.9% lower vaccination rate than Nevada Cumulative deaths per 100k: 389 (97 total deaths) 29.2% more deaths per 100k residents than Nevada Cumulative cases per 100k: 24,834 (6,186 total cases) 13.9% more cases per 100k residents than Nevada
Population that is fully vaccinated: 55.7% (2,510 fully vaccinated) 5.6% lower vaccination rate than Nevada Cumulative deaths per 100k: 333 (15 total deaths) 10.6% more deaths per 100k residents than Nevada Cumulative cases per 100k: 20,422 (920 total cases) 6.3% less cases per 100k residents than Nevada
Population that is fully vaccinated: 55.9% (1,266,403 fully vaccinated) 5.3% lower vaccination rate than Nevada Cumulative deaths per 100k: 315 (7,145 total deaths) 4.7% more deaths per 100k residents than Nevada Cumulative cases per 100k: 22,174 (502,618 total cases) 1.7% more cases per 100k residents than Nevada
Population that is fully vaccinated: 62.8% (35,104 fully vaccinated) 6.4% higher vaccination rate than Nevada Cumulative deaths per 100k: 345 (193 total deaths) 14.6% more deaths per 100k residents than Nevada Cumulative cases per 100k: 25,279 (14,135 total cases) 16.0% more cases per 100k residents than Nevada
Population that is fully vaccinated: 62.9% (296,661 fully vaccinated) 6.6% higher vaccination rate than Nevada Cumulative deaths per 100k: 235 (1,107 total deaths) 21.9% less deaths per 100k residents than Nevada Cumulative cases per 100k: 21,239 (100,144 total cases) 2.6% less cases per 100k residents than Nevada
